Papillary thyroid cancer

LUNGevity and RETpositive Issue RFA for Pan-Cancer Research Focused on RET Biomarker

Retrieved on: 
Thursday, January 25, 2024
Medullary thyroid cancer, Patient, Papillary thyroid cancer, Thought, Research, Cancer, Lung cancer, RET, Doctor of Philosophy, Biomarker, MPH, Breast, RFA, Pharmaceutical industry

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation is proud to announce the 2024 Request for Applications (RFA) for our first pan-cancer research award program—the RETpositive/LUNGevity Translational Research Award for RET-positive Cancer.

Key Points: 
  • WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation is proud to announce the 2024 Request for Applications (RFA) for our first pan-cancer research award program—the RETpositive/LUNGevity Translational Research Award for RET-positive Cancer.
  • Currently, two RET tyrosine kinase inhibitors are approved for the treatment of cancers carrying the RET biomarker.
  • In this award program, RETpositive, a patient-led advocacy group focused on increasing awareness and supporting research for RET-positive cancers, seeks to fund high-impact research that transforms the future for all patients diagnosed with RET-positive cancer by changing RET-positive cancer into a chronic or curable condition.
  • RETpositive and LUNGevity successfully partnered in 2022 to fund research focused on RET-positive lung cancer.

Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation

Retrieved on: 
Wednesday, December 20, 2023
Food, Classification, Lymph, Risk management, FDA, Papillary thyroid cancer, IDE, Breakthrough, Mayo Clinic, OTCQB, Patient, Radiation, Pharmaceutical industry

Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.

Key Points: 
  • Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.
  • Dr. Mike Korenko stated “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions.
  • The analysis in our Risk Management Report concluded that RadioGel™ is intrinsically safe and our animal therapy data verified its effectiveness.
  • The FDA’s Breakthrough Devices program facilitates accelerated development and expedites the review of breakthrough technologies to help patients potentially gain timely access to technologies that can provide more effective treatment options.

EQS-News: RadioGel Precision Radionuclide Therapy Receives FDA Breakthrough Device Designation

Retrieved on: 
Thursday, December 21, 2023
FDA, Risk management, Radiation, Lymph, Patient, OTCQB, Breakthrough, Food, Mayo Clinic, Papillary thyroid cancer, IDE, Classification, Pharmaceutical industry

RICHLAND, WA - (NewMediaWire) - December 20, 2023 -- Vivos Inc. (OTCQB: RDGL), is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.

Key Points: 
  • RICHLAND, WA - ( NewMediaWire ) - December 20, 2023 -- Vivos Inc. (OTCQB: RDGL), is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.
  • Dr. Mike Korenko stated, “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions.
  • The analysis in our Risk Management Report concluded that RadioGel™ is intrinsically safe and our animal therapy data verified its effectiveness.
  • The FDA’s Breakthrough Devices program facilitates accelerated development and expedites the review of breakthrough technologies to help patients potentially gain timely access to technologies that can provide more effective treatment options.

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 16, 2023
PDAC, NETS, Table, Neoplasm, Survival, ICB, Protein, Acquisition, CEACAM1, Patient, 5T4, SAB, Coronavirus Scientific Advisory Board, NK, Research, NET, Net, CD8, Average cost, TME, Neutrophil extracellular traps, PD-1, Safety, Cancer, STAT3, AACR, International, Papillary thyroid cancer, Therapeutic index, American Association for Cancer Research, Biomarker, SOC, MD Anderson Cancer Center, Jefferies Group, Administration, CM24, University, TASE, Immune system, Escape Room, Infrared spectroscopy correlation table, CRC, IRS1, ADS, Cetuximab, Trial of the century, Drug resistance, State Administrative Expenses, Clinical trial, Tumor microenvironment, Nivolumab, Pharmaceutical industry, Vaccine

REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2023.

Key Points: 
  • The acquisition provides Purple Biotech with a technology platform for tri-specific antibody compounds and offers the potential to further expand to additional targets.
  • On March 16, 2023, Purple Biotech shared new results from exploratory analyses from a Phase 1 dose escalation study that assessed the safety and tolerability of CM24 plus nivolumab ( NCT04731467 ).
  • On April 19, 2023, Purple Biotech announced research findings at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando.
  • Purple Biotech announced on April 25, 2023, the inauguration of its Scientific Advisory Board (SAB).

First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma

Retrieved on: 
Monday, April 17, 2023
Well, Class II, RECIST, DL 2, A2, MEK, Doctor of Philosophy, Plasma, MD, Patient, Carcinoma, KNTE, PRS, MBBS, Half-life, Response evaluation criteria in solid tumors, FACP, University of Virginia Cancer Center, Lung cancer, Binimetinib, Combination therapy, Neoplasm, Grade, Abstract, Skin, PR, Safety, RAF, NRAS, DNA, Index, AACR, Alanine transaminase, Papillary thyroid cancer, American Association for Cancer Research, BRAF, NSCLC, IC50, Colorectal cancer, SAN, MTD, ORR, Probability, Grade 3, Trae tha Truth, Part, Physician, Melanoma, Annual general meeting, Toxic leukoencephalopathy, SD, Pharmaceutical industry, Vaccine, Phosphorus, Generic drug, Medical imaging, Nursing, Cmax

“The exarafenib dose escalation data provide striking proof of concept for a monotherapy pan-RAF inhibitor,” said Alexander Spira, MD, PhD, FACP, co-director, Virginia Cancer Specialists Research Institute.

Key Points: 
  • “The exarafenib dose escalation data provide striking proof of concept for a monotherapy pan-RAF inhibitor,” said Alexander Spira, MD, PhD, FACP, co-director, Virginia Cancer Specialists Research Institute.
  • Treated patients included those with solid tumors driven by BRAF Class I (41.7%), Class II (13.3%) and Class III (30%) alterations or melanoma with NRAS mutations (15%).
  • Dose limiting toxicities observed at the highest dose level (400 mg bid) were Grade 3 acneiform rash (n=1) and Grade 3 macular rash (n=1).
  • Kinnate will prioritize development of the exarafenib combination in patients with NRAS mutant melanoma.

Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study

Retrieved on: 
Thursday, March 16, 2023
Tumor microenvironment, DNA, NETS, Cancer, Survival, Trial of the century, Escape Room, Biomarker, PDAC, CEACAM1, Patient, CM24, CRC, TME, PD-1, Safety, Drug resistance, Papillary thyroid cancer, Neutrophil, Nivolumab, Neoplasm, Pharmaceutical industry, Vaccine

REHOVOT, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome tumor immune evasion and drug resistance, today provided new results from exploratory analyses conducted as part of a Phase 1 dose escalation study that assessed the safety and tolerability of CM24 plus nivolumab (NCT04731467). The study enrolled 14 patients with advanced cancers including 11 patients with pancreatic adenocarcinoma (PDAC), two patients with colorectal adenocarcinoma (CRC) and one patient with papillary thyroid cancer. The analyses conducted in eight evaluable PDAC patients demonstrate clinically meaningful and durable reductions in serum myeloperoxidase, a biomarker for NETs, following treatment with CM24 plus nivolumab, immediately and 15 days after the first administration. In addition, analyses of tumor samples derived from the evaluable PDAC patients suggest that patient survival may be positively associated with higher levels of CEACAM1+ tumor-infiltrating lymphocytes in the TME. These results, along with additional data from this clinical study, are part of the Company’s effort aimed at identifying and evaluating the potential utility of a biomarker to optimize patient selection and treatment. Further study results on this topic will be presented at an upcoming medical conference.

Key Points: 
  • These results, along with additional data from this clinical study, are part of the Company’s effort aimed at identifying and evaluating the potential utility of a biomarker to optimize patient selection and treatment.
  • The Company is evaluating CM24 in patients with metastatic pancreatic cancer (PDAC) in combination with the PD-1 inhibitor nivolumab and chemotherapy in a randomized Phase 2 study.
  • The primary endpoint of this Phase 2 study is to evaluate preliminary efficacy through overall survival in second-line PDAC.
  • “We look forward to further data that may establish these findings in our ongoing randomized Phase 2 clinical study evaluating CM24 in combination with nivolumab and chemotherapy for treatment of PDAC."

Thyroid Cancer Expert: 5 Best Ways to Diagnose America's Fastest Growing Cancer

Retrieved on: 
Thursday, October 6, 2022
News, Thyroid cancer, Lymph, Finger, Neck pain, Hospital, Head, Woman, Diagnosis, Adrenal tumor, Neck, Lymph node, Neoplasm, Patient, HCA, Thyroid, Surgeon, Cell, Cancer, Awareness, CT, Papillary thyroid cancer, Thyroid nodule, Headache, Aspirants (web series), FNA, Health, Complaint, Nursing, Exocrine gland, Center, Medical device, Medical imaging, Dietary supplement, Dentistry, Trapping

TAMPA, Fla., Oct. 6, 2022 /PRNewswire/ -- Dr. Nate Walsh, a recognized expert on thyroid cancer, has published a new article on the best ways to diagnose thyroid cancer for Thyroid Cancer Awareness Month.

Key Points: 
  • TAMPA, Fla., Oct. 6, 2022 /PRNewswire/ -- Dr. Nate Walsh, a recognized expert on thyroid cancer, has published a new article on the best ways to diagnose thyroid cancer for Thyroid Cancer Awareness Month.
  • Thyroid cancer is the fastest growing cancer in the US, and is the 5th most common cancer in women.
  • First way to diagnose thyroid cancer: FNA or Needle Biopsy
    "A fine needle aspiration biopsy (FNA or needle biopsy) remains the mainstay in the diagnosis of thyroid cancer," says Dr. Walsh.
  • Second way to diagnose thyroid cancer: Thyroid ultrasound
    "An excellent ultrasound can be enough to make the diagnosis of thyroid cancer," says Dr. Walsh.

Clayman Thyroid Center Releases New 1 Min Video to Self-Screen for Thyroid Cancer, Among Other Resources, For Thyroid Cancer Awareness Month

Retrieved on: 
Thursday, September 22, 2022
YouTube, The Center, Papillary thyroid cancer, Health, Thyroid cancer, Graves' disease, Awareness, Woman, Thyroid, Nursing, Center, Hospital, Internet, Neoplasm, Adrenal tumor, Patient, Cancer, Diagnosis, Exocrine gland, Surgeon, HCA, Follicular thyroid cancer, Neck, Medical imaging, Trapping, Dentistry

In the new thyroid cancer self-check video , released by the Clayman Thyroid Center for Thyroid Cancer Awareness Month, Dr. Rashmi Roy will walk you through how to perform this self-check in less than one minute.

Key Points: 
  • In the new thyroid cancer self-check video , released by the Clayman Thyroid Center for Thyroid Cancer Awareness Month, Dr. Rashmi Roy will walk you through how to perform this self-check in less than one minute.
  • Previous self-check videos released by the Clayman Thyroid Center team helped countless people take a step toward advocating for their own health.
  • In addition to videos, the Clayman Thyroid Center is also publishing articles written by expert thyroid surgeons for Thyroid Cancer Awareness Month.
  • About the Clayman Thyroid Center:
    Founded by one of the nation's best-known thyroid surgeons, the Clayman Thyroid Center is the highest volume thyroid cancer referral center inthe United States.

Fore Biotherapeutics Presents Positive Interim Data From Phase 1/2a Trial Evaluating FORE8394 in Patients With Advanced Tumors With Activating BRAF Alterations at ESMO 2022

Retrieved on: 
Monday, September 12, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Adult, Glioma, Phase II, Papillary thyroid cancer, Central nervous system, Safety, MAPK, Twitter, MD, Diarrhea, Ovarian cancer, Neoplasm, Colorectal cancer, LinkedIn, European Society for Medical Oncology, CRC, BRAF, Cobicistat, Patient, AES, Cancer, Fore, ORR, Doctor of Philosophy, Drug development, CNS, Genomics, Nausea, Fatigue, Memorial Sloan Kettering Cancer Center, PFS, HIV disease progression rates, CYP3A4, PR, RAF, ESMO, Pharmaceutical industry, Medical imaging

"These results are very encouraging and reinforce our conviction that FORE8394 has the potential to provide meaningful benefit to patients with BRAF-mutated cancers with high unmet need.

Key Points: 
  • "These results are very encouraging and reinforce our conviction that FORE8394 has the potential to provide meaningful benefit to patients with BRAF-mutated cancers with high unmet need.
  • We are embarking upon developing this novel treatment and are on track to initiate our global Phase 2 trial next quarter.
  • "We're excited that the majority of gliomas demonstrated response and the prolonged benefit and tolerability experienced by some patients receiving FORE8394.
  • Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients.

Thyroid Cancer Awareness Month: Top 10 Things to Know About Thyroid Cancer from World's Leading Thyroid Surgeons

Retrieved on: 
Thursday, September 1, 2022
Neoplasm, Thyroid cancer, Cancer, Ageing, Research, Papillary thyroid cancer, Man, Incidence, CT, Awareness, Risk, Specialization, Radiation, Pathology, Neck, Marie Cassidy, Thyroid, Hospital, Biopsy, Lymph, Surgeon, Medical director, Patient, Center, Prevalence, Radar, Woman, Travel, Medical imaging, Dietary supplement, Birth control, Dentistry

TAMPA, Fla., Sept. 1, 2022 /PRNewswire/ -- 

Key Points: 
  • There are two main risk factors for thyroid cancer: a family history of thyroid cancer, and significant exposure to radiation.
  • If an immediate family member has papillary thyroid cancer (the most common type of thyroid cancer), their first-degree relatives have up to ten times increased risk of developing a thyroid cancer.
  • Here are the top 5 thyroid cancer symptoms:
    5) What does a thyroid cancer evaluation entail?
  • About the Clayman Thyroid Center:
    Founded by one of the nation's best-known thyroid surgeons, the Clayman Thyroid Center is the highest volume thyroid cancer referral center in the United States.